Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05180006
Title Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris

Her2-receptor positive breast cancer

triple-receptor negative breast cancer



Atezolizumab + Pertuzumab + Trastuzumab

Atezolizumab + Ipatasertib

Atezolizumab + Bevacizumab

Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
Gustave Roussy Recruiting Villejuif 94800 France Details
*Shaded cells indicate that there was no data available from for the field